Enzon Pharmaceuticals, Inc.
Records under this name other than patents Enzon Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Enzon Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,807,436 | Recombinant host for producing L-asparaginase II Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,584,675 | Connector enabling multiple sampling of sealed environment Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,071,741 | Stable recombinant adenosine deaminase Formerly held In force · USPTO record | In force | USPTO record | |
| US 8,741,283 | Adenosine deaminase anticancer therapy Formerly held In force · USPTO record | In force | USPTO record | |
| US 9,506,060 | Lna Antisense Oligonucleotides for the Modulation of Myc Expression Formerly held Lapsed on the fee record Ended Nov 29, 2024 · High confidence | Lapsed on the fee record | Ended Nov 29, 2024 | High confidence |
| US 7,939,507 | Potent LNA oligonucleotides for the inhibition of HIF-1a expression Formerly held Lapsed on the fee record Ended May 10, 2023 · USPTO record | Lapsed on the fee record | Ended May 10, 2023 | USPTO record |
| US 7,846,911 | Oligomeric compounds for the modulation of HIF-1alpha expression Formerly held Lapsed on the fee record Ended Dec 7, 2022 · USPTO record | Lapsed on the fee record | Ended Dec 7, 2022 | USPTO record |
| US 8,785,617 | Oligomeric compounds for the modulation of HIF-1A expression Formerly held Lapsed on the fee record Ended Jul 22, 2022 · USPTO record | Lapsed on the fee record | Ended Jul 22, 2022 | USPTO record |
| US 7,737,125 | LNA antagonists targeting the androgen receptor Formerly held Lapsed on the fee record Ended Jun 15, 2022 · USPTO record | Lapsed on the fee record | Ended Jun 15, 2022 | USPTO record |
| US 7,737,264 | Oligomeric compounds for the modulation HIF-1α expression Formerly held Lapsed on the fee record Ended Jun 15, 2022 · USPTO record | Lapsed on the fee record | Ended Jun 15, 2022 | USPTO record |